Efficacy and safety of adjuvant targeted immunotherapy for hepatocellular carcinoma with high recurrence risks after hepatectomy

Table 1 Patterns of initial recurrence and subsequent management strategies following surgery, n (%)

	Total (n = 109)	ATG (n = 47)	SG (n = 62)	P value
Recurrence site				0.790
Intrahepatic	98 (89.9)	42 (89.4)	56 (90.3)
Extrahepatic	5 (4.6)	3 (6.4)	2 (3.2)
Intrahepatic + extrahepatic	6 (5.5)	2 (4.3)	4 (6.5)
Post relapse treatment				0.475
Re-hepatectomy	30 (27.5)	11 (23.4)	19 (30.6)
Local + systemic treatment	18 (16.5)	7 (14.9)	11 (17.7)
Local therapy + radiofrequency ablation + systemic therapy	18 (16.5)	8 (17.0)	10 (16.1)
Radiofrequency ablation + systemic therapy	14 (12.8)	7 (14.9)	7 (11.3)
Local treatment	9 (8.3)	2 (4.3)	7 (11.3)
Radiofrequency ablation	8 (7.3)	6 (12.8)	2 (3.2)
Systemic therapy	6 (5.5)	4 (8.5)	2 (3.2)
Resection of extrahepatic metastases	5 (4.6)	2 (4.3)	3 (4.8)
Liver transplant	1 (0.9)	0 (0.0)	1 (1.6)

ATG: Adjuvant therapy group; SG: Surgery-alone group.